These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26112144)

  • 1. Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity.
    Bizzarri BM; Tortolini S; Rotelli L; Botta G; Saladino R
    Curr Med Chem; 2015; 22(36):4138-65. PubMed ID: 26112144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
    Atlas D
    CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Biological Evaluation of Novel Selenyl and Sulfur-l-Dopa Derivatives as Potential Anti-Parkinson's Disease Agents.
    Di Stefano A; Marinelli L; Eusepi P; Ciulla M; Fulle S; Di Filippo ES; Magliulo L; Di Biase G; Cacciatore I
    Biomolecules; 2019 Jun; 9(6):. PubMed ID: 31216771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual effects of L-DOPA on nigral dopaminergic neurons.
    Guatteo E; Yee A; McKearney J; Cucchiaroni ML; Armogida M; Berretta N; Mercuri NB; Lipski J
    Exp Neurol; 2013 Sep; 247():582-94. PubMed ID: 23481547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanding the repertoire of L-DOPA's actions: A comprehensive review of its functional neurochemistry.
    De Deurwaerdère P; Di Giovanni G; Millan MJ
    Prog Neurobiol; 2017 Apr; 151():57-100. PubMed ID: 27389773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies.
    Sharma S; Singh S; Sharma V; Singh VP; Deshmukh R
    Biomed Pharmacother; 2015 Mar; 70():283-93. PubMed ID: 25776513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-loaded nanoparticles for the treatment of Parkinson's disease.
    van Vliet EF; Knol MJ; Schiffelers RM; Caiazzo M; Fens MHAM
    J Control Release; 2023 Aug; 360():212-224. PubMed ID: 37343725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
    Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
    Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room.
    Paul R; Borah A
    Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRK-820, a selective kappa opioid receptor agonist, could effectively ameliorate L-DOPA-induced dyskinesia symptoms in a rat model of Parkinson's disease.
    Ikeda K; Yoshikawa S; Kurokawa T; Yuzawa N; Nakao K; Mochizuki H
    Eur J Pharmacol; 2009 Oct; 620(1-3):42-8. PubMed ID: 19686730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetyl-L-methionyl-L-Dopa-methyl ester as a dual acting drug that relieves L-Dopa-induced oxidative toxicity.
    Minelli A; Conte C; Prudenzi E; Cacciatore I; Cornacchia C; Taha E; Pinnen F
    Free Radic Biol Med; 2010 Jul; 49(1):31-9. PubMed ID: 20307650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons From VMAT2 heterozygote knockout mice.
    Kariya S; Takahashi N; Hirano M; Ueno S
    J Mol Neurosci; 2005; 27(3):277-79. PubMed ID: 16280597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromolecular imaging, a nanobiotechnology for Parkinson's disease: advancing pharmacotherapy for personalized medicine.
    Broderick PA; Wenning L; Li YS
    J Neural Transm (Vienna); 2017 Jan; 124(1):57-78. PubMed ID: 27796511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
    Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.